Biogen, a stalwart of the global drug industry for the past four decades, is perilously poised for 2022.
The company’s Tuesday decisions to replace CEO Michel Vounatsos and cut nearly all spending marketing the Alzheimer’s disease treatment Aduhelm resolved some of the questions swirling around the embattled biotech.
Create a display name to comment
This name will appear with your comment
